Experience
Elan Pharmaceuticals, Inc.
Eon Labs, Inc.
Represented Elan in Hatch-Waxman patent infringement actions involving Skelaxin®, including in two successful appeals before the Federal Circuit.
Elan Pharmaceuticals, Inc. v. Eon Labs, Inc., 1:04-cv-05540, E.D.N.Y., Judges Mauskopf, Trager, Mann
Elan Pharmaceuticals, Inc. v. Eon Labs, Inc., 09-1437, -1438, Fed. Cir., Judges Bryson, Gajarsa, Prost
Eon Labs, Inc. v. Elan Pharmaceuticals, Inc., 11-1070, Fed. Cir., Judges Newman, Rader, Reyna
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
AbbVie Inc.
Israel Bio-Engineering Project v. Amgen Inc., et al.
Amgen Inc., Immunex Corp.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Innovative Therapies, Inc. v. Kinetic Concepts, Inc.
Kinetic Concepts, Inc.
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc.
Valeant Pharmaceuticals International, Inc.
District court ruling maintains patent and regulatory protection of Otsuka’s Abilify®
Otsuka Pharmaceutical Co., Ltd.
Highmark, Inc. v. Allcare Health Management System, Inc.
Allcare Health Management System, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.